Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Mesial temporal lobe epilepsy with hippocampal sclerosis is a rare epilepsy syndrome defined by seizures originating in limbic areas of the mesial temporal lobe, particularly in the hippocampus, amygdala, and in the parahippocampal gyrus and its connections, and hippocampal sclerosis, usually unilateral or asymmetric. It is frequently associated with an initial precipitating event, such as febrile seizures, hypoxia, intracranial infection or head trauma, most often occurring in the first five years of life, followed by a latent period without seizures. Typical seizures consist of a characteristic aura that is frequently a rising epigastric sensation associated with emotional disturbances, illusions, and autonomic symptoms (widened pupils, palpitations), progressive impairment of consciousness, oro-alimentary automatisms (lip smacking, chewing, licking, tooth grinding), behavioral arrest, head deviation, dystonic postures, hand and verbal automatisms. Seizures are followed by postictal dysfunction. Initially, seizures are easily controlled with antiepileptic drugs, later they frequently become refractory and associated with progressive behavioral changes and memory deficits.
Biomarker and diagnostic research for mesial temporal lobe epilepsy with hippocampal sclerosis has been reported in the published literature.
1 clinical trial registered. Interventions under study include procedural interventions. Pipeline includes 1 NA. Research is primarily sponsored by academic and government institutions.
39 publications have been identified in PubMed for mesial temporal lobe epilepsy with hippocampal sclerosis. Research spans Basic Science / Preclinical (31%), Diagnostic / Biomarker (23%), and Clinical Trial Publication (21%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 12 |
Data assembled from 4 of 12 sources · Last updated Sep 20, 2026, 1:01 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Testing and diagnosis research | 9 | 23% |
Clinical study results | 8 | 21% |
Disease patterns and progression | 5 | 13% |
Research summaries | 4 | 10% |
Patient case studies | 1 | 3% |
Tang T (2026). [PMID: 41618744](https://pubmed.ncbi.nlm.nih.gov/41618744/). *CNS neuroscience & therapeutics*. [Basic Science / Preclinical]
Kawamura Y (2026). [PMID: 41696864](https://pubmed.ncbi.nlm.nih.gov/41696864/). *Journal of medical virology*. [Basic Science / Preclinical]
Araújo JQ (2026). [PMID: 41235465](https://pubmed.ncbi.nlm.nih.gov/41235465/). *Epileptic disorders : international epilepsy journal with videotape*. [Epidemiology / Natural History]
Yadav N (2026). [PMID: 41499010](https://pubmed.ncbi.nlm.nih.gov/41499010/). *Neurochemical research*. [Basic Science / Preclinical]
Turk BG (2026). [PMID: 41908687](https://pubmed.ncbi.nlm.nih.gov/41908687/). *Epilepsy & behavior reports*. [Basic Science / Preclinical]
Seiler O (2026). [PMID: 41396055](https://pubmed.ncbi.nlm.nih.gov/41396055/). *Epileptic disorders : international epilepsy journal with videotape*. [Clinical Trial Publication]
Silva L (2026). [PMID: 41702218](https://pubmed.ncbi.nlm.nih.gov/41702218/). *Epilepsy & behavior : E&B*. [Diagnostic / Biomarker]
Zhu F (2026). [PMID: 41925386](https://pubmed.ncbi.nlm.nih.gov/41925386/). *Epilepsia*. [Epidemiology / Natural History]
Deleu B (2026). [PMID: 41104578](https://pubmed.ncbi.nlm.nih.gov/41104578/). *Epilepsia*. [Review / Meta-Analysis]
Martínez-Juárez IE (2026). [PMID: 42030212](https://pubmed.ncbi.nlm.nih.gov/42030212/). *Neuroimmunomodulation*. [Review / Meta-Analysis]